Novo Nordisk stock jumped more than 2% in trading Wednesday after beating Wall Street's profit estimates for the first ...

Eli Lilly is proving that being second but better can also pay. Zepbound, the American firm’s weight-loss jab, was approved ...

Andrew Dudum cofounded online pharmacy Hims & Hers eight years ago, when he was 27 years old. He’s now the latest to make a ...

Hims & Hers stock has surged due to impressive quarterly results, rapid weight-loss product expansion, and a strategic Novo ...

Medicare recipients suffering from obesity must pay out of pocket for weight loss drugs like Wecovy and Zepbound.

We expected miracles—what we got was a legal minefield. As GLP-1 drugs like Ozempic reshape bodies and bottom lines, a ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The celebrated actress has lost more than 100Ib after turning to controversial diabetes jab Ozempic - now better known for its impact on tackling obesity ...

Novo Nordisk's obesity sales grew 55% to reach DKK 8.4 billion ($1.2 billion) last year, led by Wegovy with a supporting role for older, once-daily injectable Saxenda (liraglutide).

Novo Nordisk is currently leading the market for incretin therapies with semaglutide-based products Ozempic for type 2 diabetes and Wegovy for obesity, but is coming under competitive pressure ...

A doctor has issued an warning as to why Ozempic shouldn't be used for weight loss as it does one alarming thing to body.

On Wednesday afternoon, the Fed left interest rates unchanged at a range of 4.25% to 4.5% for the third straight meeting. The ...